Literature DB >> 8932338

Mutation of the TP53 gene and allelic imbalance at chromosome 17p13 in ductal carcinoma in situ.

K E Munn1, R A Walker, L Menasce, J M Varley.   

Abstract

A panel of 36 cases of preinvasive breast lesions, including 35 cases of ductal carcinoma in situ (DCIS), has been examined for mutation of TP53, allelic imbalance (AI) on 17p13, and expression of TP53, in a number of cases, has been studied using immunohistochemistry. Areas of DCIS, with or without adjacent invasive or benign cells, have been separately microdissected from paraffin-embedded sections and analysed by PCR for genetic changes to chromosome 17p13. TP53 mutations and AI on 17p have been identified in cases of 'pure' DCIS as well as those with associated invasive carcinoma and, furthermore, have been identified in well-differentiated lesions as well as poorly differentiated ones.

Entities:  

Mesh:

Year:  1996        PMID: 8932338      PMCID: PMC2074864          DOI: 10.1038/bjc.1996.592

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  48 in total

1.  Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction.

Authors:  M Orita; Y Suzuki; T Sekiya; K Hayashi
Journal:  Genomics       Date:  1989-11       Impact factor: 5.736

2.  Codon 72 polymorphism of the TP53 gene.

Authors:  S Ara; P S Lee; M F Hansen; H Saya
Journal:  Nucleic Acids Res       Date:  1990-08-25       Impact factor: 16.971

3.  An improved method for directly sequencing PCR amplified material using dimethyl sulphoxide.

Authors:  P R Winship
Journal:  Nucleic Acids Res       Date:  1989-02-11       Impact factor: 16.971

4.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro.

Authors:  J Bártek; J Bártková; B Vojtĕsek; Z Stasková; A Rejthar; J Kovarík; D P Lane
Journal:  Int J Cancer       Date:  1990-11-15       Impact factor: 7.396

5.  The clinical significance of pre-invasive breast carcinoma.

Authors:  P P Rosen; D W Braun; D E Kinne
Journal:  Cancer       Date:  1980-08-15       Impact factor: 6.860

6.  Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.

Authors:  R S Cornelis; M van Vliet; C B Vos; A M Cleton-Jansen; M J van de Vijver; J L Peterse; P M Khan; A L Børresen; C J Cornelisse; P Devilee
Journal:  Cancer Res       Date:  1994-08-01       Impact factor: 12.701

7.  Relative efficiency of denaturing gradient gel electrophoresis and single strand conformation polymorphism in the detection of mutations in exons 5 to 8 of the p53 gene.

Authors:  C Moyret; C Theillet; P L Puig; J P Molés; G Thomas; R Hamelin
Journal:  Oncogene       Date:  1994-06       Impact factor: 9.867

8.  A comparison of the results of long-term follow-up for atypical intraductal hyperplasia and intraductal hyperplasia of the breast.

Authors:  F A Tavassoli; H J Norris
Journal:  Cancer       Date:  1990-02-01       Impact factor: 6.860

9.  p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.

Authors:  F P O'Malley; C L Vnencak-Jones; W D Dupont; F Parl; S Manning; D L Page
Journal:  Lab Invest       Date:  1994-07       Impact factor: 5.662

10.  c-erbB-2 expression in benign and malignant breast disease.

Authors:  B A Gusterson; L G Machin; W J Gullick; N M Gibbs; T J Powles; C Elliott; S Ashley; P Monaghan; S Harrison
Journal:  Br J Cancer       Date:  1988-10       Impact factor: 7.640

View more
  8 in total

1.  Primary squamous cell carcinoma of the endometrium unrelated to human papilloma virus: a molecular study.

Authors:  Giovanna Giordano; Silvia Pizzi; Cinzia Azzoni; Lorena Bottarelli; Tiziana D'Adda
Journal:  Pathol Oncol Res       Date:  2013-02-21       Impact factor: 3.201

2.  p53 mutations and expression in breast carcinoma in situ.

Authors:  J Lukas; N Niu; M F Press
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

3.  Loss of heterozygosity and microsatellite instability in breast hyperplasia. No obligate correlation of these genetic alterations with subsequent malignancy.

Authors:  M Kasami; C L Vnencak-Jones; S Manning; W D Dupont; D L Page
Journal:  Am J Pathol       Date:  1997-06       Impact factor: 4.307

4.  Breast ductal carcinoma in situ carry mutational driver events representative of invasive breast cancer.

Authors:  Jia-Min B Pang; Peter Savas; Andrew P Fellowes; Gisela Mir Arnau; Tanjina Kader; Ravikiran Vedururu; Chelsee Hewitt; Elena A Takano; David J Byrne; David Yh Choong; Ewan Ka Millar; C Soon Lee; Sandra A O'Toole; Sunil R Lakhani; Margaret C Cummings; G Bruce Mann; Ian G Campbell; Alexander Dobrovic; Sherene Loi; Kylie L Gorringe; Stephen B Fox
Journal:  Mod Pathol       Date:  2017-03-24       Impact factor: 7.842

5.  Are there low-penetrance TP53 Alleles? evidence from childhood adrenocortical tumors.

Authors:  J M Varley; G McGown; M Thorncroft; L A James; G P Margison; G Forster; D G Evans; M Harris; A M Kelsey; J M Birch
Journal:  Am J Hum Genet       Date:  1999-10       Impact factor: 11.025

6.  Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up.

Authors:  A M Thompson; D N Crichton; R A Elton; M F Clay; U Chetty; C M Steel
Journal:  Br J Cancer       Date:  1998-03       Impact factor: 7.640

7.  Genetic alterations on chromosome 16 and 17 are important features of ductal carcinoma in situ of the breast and are associated with histologic type.

Authors:  C B Vos; N T ter Haar; C Rosenberg; J L Peterse; A M Cleton-Jansen; C J Cornelisse; M J van de Vijver
Journal:  Br J Cancer       Date:  1999-12       Impact factor: 7.640

Review 8.  Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast.

Authors:  Jia-Min B Pang; Kylie L Gorringe; Stephen Q Wong; Alexander Dobrovic; Ian G Campbell; Stephen B Fox
Journal:  Breast Cancer Res       Date:  2015-06-16       Impact factor: 6.466

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.